TOUJEO®
DOSING IN PATIENTS WITH TYPE 2 DIABETES

START[1,2] (new to basal)

Recommended dose:	**0.2 U/kg OD**
Diabetes Canada suggested dose:	**10 units OD**

Based on the discretion of the healthcare provider.

TRANSFER[1]

Patients on OD basal insulin:	**1:1 conversion***
Patients on BID basal insulin:	**Start TOUJEO® at 80% of previous total daily basal insulin dose**

Monitor glucose frequently in the first weeks of therapy and **titrate the dose of TOUJEO®** per instructions and the dose of other glucose lowering therapies per standard of care to minimize the risk of hyperglycemia when transferring patients to TOUJEO®.[1]

Titration example from a study

TITRATE your patients to target[2,3]

Perform fasting SMBG ≥1 x/day and self-titrate to target

FBG >7.0 mmol/L	**+1 unit**
TARGET FBG 4.0–7.0 mmol/L	Keep the **same dose**

Dosage adjustments should be based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.[1]

Adapted from TOUJEO® SoloSTAR® Product Monograph, the Diabetes Canada Clinical Practice Guidelines Expert Committee, 2018 and Yale JF, et al. Please refer to the Product Monograph for complete dosing and administration instructions.

CONSIDERATIONS

- Consider a lower starting dose, slower titration and higher targets for elderly or normal weight subjects[2]

Please refer to the Diabetes Canada Clinical Practice Guidelines for additional considerations.

The TOUJEO® SoloSTAR® Product Monograph outlines that the full glucose lowering effect of TOUJEO® may not be apparent for at least 5 days.[1†]

TOUJEO® is indicated for once-daily subcutaneous administration in the treatment of adult patients (≥18 years) with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for glycemic control.[1]

OD=once daily; BID=twice daily; SMBG=self-monitoring blood glucose; FBG=fasting blood glucose.
* LANTUS® and TOUJEO® are not bioequivalent and are not directly interchangeable. A higher daily TOUJEO® dose may be needed to achieve target ranges for plasma glucose level when switching from LANTUS®.
† Clinical significance has not been established.

Toujeo® insulin glargine 300 U/mL

TOUJEO®

ONE-THIRD THE VOLUME OF LANTUS® FOR THE SAME NUMBER OF UNITS[1]

LANTUS®
100 U/mL

TOUJEO®
300 U/mL

Insulin glargine 100 U/mL (LANTUS®) and insulin glargine 300 U/mL (TOUJEO®) are not bioequivalent and are therefore not interchangeable without dose adjustment



A higher daily TOUJEO® dose may be needed when switching from LANTUS® to achieve target ranges for plasma glucose level. Please refer to the TOUJEO® SoloSTAR® Product Monograph for more information on dosing.

Adapted from TOUJEO® SoloSTAR® Product Monograph.

Please consult the Product Monograph at http://products.sanofi.ca/en/toujeo-solostar.pdf for important information about:[1]

- Contraindications in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container and during episodes of hypoglycemia
- Most serious warnings and precautions regarding hypoglycemia, administration, medication errors and LANTUS® and TOUJEO® not being interchangeable
- Other relevant warnings and precautions relating to combination of insulin, including TOUJEO®, with thiazolidinediones (TZDs); risk of hyperglycemia; considering the longer onset of action of TOUJEO® before stopping intravenous (IV) insulin treatment in patients with Type 1 diabetes; hypokalemia; sodium retention and edema; fluid retention and heart failure with concomitant use of peroxisome proliferator-activated receptor (PPAR)-gamma agonists TZDs; patients with renal impairment and hepatic impairment; risk of allergic reactions, injection site reactions, lipodystrophy and lipoatrophy, rash and antibody formation; risk of visual impairment, worsening of diabetic retinopathy and transient amaurosis; pregnant or nursing women; and geriatrics
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph may also be obtained by calling 1.888.852.6887.

References: 1. TOUJEO® SoloSTAR® Product Monograph, sanofi-aventis Canada Inc., July 4, 2018. **2.** Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabetes* 2018;42(Suppl 1):S1–S325. **3.** Yale JF, et al. TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. *Can J Diabetes* 2017:1–7.

SACA.TJO.19.03.0186E 50129624

SANOFI

MEMBER OF INNOVATIVE MEDICINES CANADA

PAAB

MARGE DE DÉGAGEMENT CLEAR SPACE
Position FSC
– minimum –
CLEAR SPACE MARGE DE DÉGAGEMENT

Toujeo®
insulin glargine 300 U/mL